Phân tích tính tương hỗ trong ức chế các tế bào ung thư vú xâm lấn giữa paclitaxel và thymoquinone

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660 Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S (2022) Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast 66:15–23. https://doi.org/10.1016/j.breast.2022.08.010 Gupta GK, Collier AL, Lee D, Hoefer RA, Zheleva V, van Siewertsz LL, Tang-Tan AM, Guye ML, Chang DZ, Winston JS, Samli B, Jansen RJ, Petricoin EF, Goetz MP, Bear HD, Tang AH (2020) Perspectives on triple-negative breast Cancer: current treatment strategies, unmet needs, and potential targets for future therapies. Cancers 12(9):2392. https://doi.org/10.3390/cancers12092392 Bozorgi A, Bozorgi M, Khazaei M (2022) Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects. Cell Oncol 45(5):755–777. https://doi.org/10.1007/s13402-022-00700-w Abu Samaan TM, Samec M, Liskova A, Kubatka P, Büsselberg D (2019) Paclitaxel’s mechanistic and clinical effects on breast Cancer. Biomolecules 9(12):789. https://doi.org/10.3390/biom9120789 Zhu L, Chen L (2019) Progress in research on paclitaxel and tumor immunotherapy. Cell Mol Biol Lett 24(1):40. https://doi.org/10.1186/s11658-019-0164-y Bernabeu E, Cagel M, Lagomarsino E, Moretton M, Chiappetta DA (2017) Paclitaxel: what has been done and the challenges remain ahead. Inte J Pharm 526(1):474–495. https://doi.org/10.1016/j.ijpharm.2017.05.016 Maloney SM, Hoover CA, Morejon-Lasso LV, Prosperi JR (2020) Mechanisms of Taxane Resistance. Cancers 12(11):3323. https://doi.org/10.3390/cancers12113323 Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H (2017) Combination therapy in combating cancer. Oncotarget 8(23):38022–38043. https://doi.org/10.18632/oncotarget.16723 Almajali B, Al-Jamal HAN, Taib WRW, Ismail I, Johan MF, Doolaanea AA, Ibrahim WN (2021) Thymoquinone, as a Novel Therapeutic candidate of cancers. Pharmaceuticals 14(4):369. https://doi.org/10.3390/ph14040369 Bozorgi A, Khazaei S, Khademi A, Khazaei M (2020) Natural and herbal compounds targeting breast cancer, a review based on cancer stem cells. Iran J Basic Med Sci 23(8):970–983. https://doi.org/10.22038/ijbms.2020.43745.10270 Saghatelyan T, Tananyan A, Janoyan N, Tadevosyan A, Petrosyan H, Hovhannisyan A, Hayrapetyan L, Arustamyan M, Arnhold J, Rotmann A-R (2020) Efficacy and safety of curcumin in combination with paclitaxel in patients with advanced, metastatic breast cancer: a comparative, randomized, double-blind, placebo-controlled clinical trial. Phytomedicine 70:153218. https://doi.org/10.1016/j.phymed.2020.153218 Chou J, Chou T (1991) Quantitation of synergism and antagonism of two or more drugs by computerized analysis. Synergism Antagonism Chemother: 223–244 Iannelli F, Roca MS, Lombardi R, Ciardiello C, Grumetti L, De Rienzo S, Moccia T, Vitagliano C, Sorice A, Costantini S, Milone MR, Pucci B, Leone A, Di Gennaro E, Mancini R, Ciliberto G, Bruzzese F, Budillon A (2020) Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition. J Exp Clin Cancer Res 39(1):213. https://doi.org/10.1186/s13046-020-01723-7 Harbeck N, Gnant M (2017) Breast cancer. Lancet 389(10074):1134–1150. https://doi.org/10.1016/s0140-6736(16)31891-8 Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2023) Efficacy and Safety of Trastuzumab as a single Agent in First-Line treatment of HER2-Overexpressing metastatic breast Cancer. J Clin Oncol 41(9):1638–1645. https://doi.org/10.1200/jco.22.02516 Koh SJ, Ohsumi S, Takahashi M, Fukuma E, Jung KH, Ishida T, Dai MS, Chang CH, Dalvi T, Walker G, Bennett J, O’Shaughnessy J, Balmaña J (2022) Correction to: prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study. Breast Cancer 29(1):189–190. https://doi.org/10.1007/s12282-021-01299-w Petrovic N, Sami A, Martinovic J, Zaric M, Nakashidze I, Lukic S, Jovanovic-Cupic S (2017) TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC. Pathol Res Pract 213(10):1264–1270. https://doi.org/10.1016/j.prp.2017.08.012 Drucker AM, Morra DE, Prieto-Merino D, Ellis AG, Yiu ZZN, Rochwerg B, Di Giorgio S, Arents BWM, Burton T, Spuls PI, Schmitt J, Flohr C (2022) Systemic immunomodulatory treatments for atopic dermatitis: update of a Living Systematic Review and Network Meta-Analysis. JAMA Dermatol 158(5):523–532. https://doi.org/10.1001/jamadermatol.2022.0455 Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J (2023) Bevacizumab in Combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal Cancer: a Randomized Phase III Study. J Clin Oncol 41(21):3663–3669. https://doi.org/10.1200/jco.22.02760 Ferraro MG, Piccolo M, Misso G, Santamaria R, Irace C (2022) Bioactivity and Development of Small Non-platinum Metal-based chemotherapeutics. Pharmaceutics 14(5):954. https://doi.org/10.3390/pharmaceutics14050954 Li G, Xu D, Sun J, Zhao S, Zheng D (2020) Paclitaxel inhibits proliferation and invasion and promotes apoptosis of breast cancer cells by blocking activation of the PI3K/AKT signaling pathway. Adv Clin Exp Med 29(11):1337–1345. https://doi.org/10.17219/acem/127681 Talib WH (2017) Regressions of breast carcinoma syngraft following treatment with piperine in combination with thymoquinone. Sci Pharm 85(3):27. https://doi.org/10.3390/scipharm85030027 Woo CC, Hsu A, Kumar AP, Sethi G, Tan KHB (2013) Thymoquinone inhibits tumor growth and induces apoptosis in a breast cancer xenograft mouse model: the role of p38 MAPK and ROS. PLoS ONE 8(10):e75356. https://doi.org/10.1371/journal.pone.0075356 Alkhatib MH, Bawadud RS, Gashlan HM (2020) Incorporation of docetaxel and thymoquinone in borage nanoemulsion potentiates their antineoplastic activity in breast cancer cells. Sci Rep 10(1):18124. https://doi.org/10.1038/s41598-020-75017-5 Zhao S, Tang Y, Wang R, Najafi M (2022) Mechanisms of cancer cell death induction by paclitaxel: an updated review. Apoptosis 27(9):647–667. https://doi.org/10.1007/s10495-022-01750-z Khing TM, Choi WS, Kim DM, Po WW, Thein W, Shin CY, Sohn UD (2021) The effect of paclitaxel on apoptosis, autophagy and mitotic catastrophe in AGS cells. Sci Rep 11(1):23490. https://doi.org/10.1038/s41598-021-02503-9 Aborehab NM, Elnagar MR, Waly NE (2021) Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J Biochem Mol Toxicol 35(2):e22638. https://doi.org/10.1002/jbt.22638 Bhattacharjee M, Upadhyay P, Sarker S, Basu A, Das S, Ghosh A, Ghosh S, Adhikary A (2020) Combinatorial therapy of Thymoquinone and Emodin synergistically enhances apoptosis, attenuates cell migration and reduces stemness efficiently in breast cancer. Biochim Biophys Acta Gen Subj 1864(11):129695. https://doi.org/10.1016/j.bbagen.2020.129695 Soni P, Kaur J, Tikoo K (2015) Dual drug-loaded paclitaxel–thymoquinone nanoparticles for effective breast cancer therapy. J Nanoparticle Res 17(1):18. https://doi.org/10.1007/s11051-014-2821-4 Şakalar Ç, İzgi K, İskender B, Sezen S, Aksu H, Çakır M, Kurt B, Turan A, Canatan H (2016) The combination of thymoquinone and paclitaxel shows anti-tumor activity through the interplay with apoptosis network in triple-negative breast cancer. Tumor Biol 37(4):4467–4477. https://doi.org/10.1007/s13277-015-4307-0 Li W, He P, Huang Y, Li Y-F, Lu J, Li M, Kurihara H, Luo Z, Meng T, Onishi M (2021) Selective autophagy of intracellular organelles: recent research advances. Theranostics 11(1):222–256. https://doi.org/10.7150/thno.49860 Boyer-Guittaut M, Poillet L, Liang Q, Bôle-Richard E, Ouyang X, Benavides GA, Chakrama F-Z, Fraichard A, Darley-Usmar VM, Despouy G (2014) The role of GABARAPL1/GEC1 in autophagic flux and mitochondrial quality control in MDA-MB-436 breast cancer cells. Autophagy 10(6):986–1003. https://doi.org/10.4161/auto.28390 Patergnani S, Missiroli S, Morciano G, Perrone M, Mantovani CM, Anania G, Fiorica F, Pinton P, Giorgi C (2021) Understanding the role of Autophagy in Cancer formation and progression is a real opportunity to treat and cure human cancers. Cancers 13(22). https://doi.org/10.3390/cancers13225622 Xu K, Zhu W, Xu A, Xiong Z, Zou D, Zhao H, Jiao D, Qing Y, Jamal MA, Wei HJ, Zhao HY (2022) Inhibition of FOXO1–mediated autophagy promotes paclitaxel–induced apoptosis of MDA–MB–231 cells. Mol Med Rep 25(2). https://doi.org/10.3892/mmr.2022.12588 Park J-H, Park S-A, Lee Y-J, Park H-W, Oh S-M (2020) PBK attenuates paclitaxel-induced autophagic cell death by suppressing p53 in H460 non-small-cell lung cancer cells. FEBS Open Bio 10(5):937–950. https://doi.org/10.1002/2211-5463.12855 Ünal TD, Hamurcu Z, Delibaşı N, Çınar V, Güler A, Gökçe S, Nurdinov N, Ozpolat B (2021) Thymoquinone inhibits proliferation and migration of MDA-MB-231 triple negative breast cancer cells by suppressing autophagy, Beclin-1 and LC3. Anticancer Agents Med Chem. 2021;21(3):355–364. https://doi.org/10.2174/1871520620666200807221047 Zhang Y, Fan Y, Huang S, Wang G, Han R, Lei F, Luo A, Jing X, Zhao L, Gu S (2018) Thymoquinone inhibits the metastasis of renal cell cancer cells by inducing autophagy via AMPK/mTOR signaling pathway. Cancer Sci 109(12):3865–3873. https://doi.org/10.1111/cas.13808